D. E. Shaw & Co., Inc. Hutchmed (China) LTD Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Hutchmed (China) LTD stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 140,473 shares of HCM stock, worth $2.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

140,473

Previous 163,606 14.14%

Holding current value

$2.4 Million

Previous $2.96 Million 20.36%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$12.08 - $18.56 $279,446 - $429,348	-23,133 Reduced 14.14%	140,473 $2.36 Million
Q4 2023 Feb 14, 2024	BUY	$16.25 - $20.23 $561,518 - $699,047	34,555 Added 26.78%	163,606 $2.96 Million
Q3 2023 Nov 14, 2023	BUY	$11.85 - $16.95 $2,287 - $3,271	193 Added 0.15%	129,051 $2.19 Million
Q2 2023 Aug 14, 2023	SELL	$10.78 - $17.73 $174,646 - $287,243	-16,201 Reduced 11.17%	128,858 $1.55 Million
Q1 2023 May 15, 2023	SELL	$13.02 - $19.87 $1.25 Million - $1.9 Million	-95,797 Reduced 39.77%	145,059 $1.89 Million

Q4 2022 Feb 14, 2023	BUY	$7.65 - $15.51 $1.84 Million - $3.74 Million	240,856 New	240,856 $3.56 Million
Q4 2021 Feb 14, 2022	SELL	$28.89 - $35.33 $934,995 - $1.14 Million	-32,364 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$35.66 - $42.94 $898,703 - $1.08 Million	25,202 Added 351.88%	32,364 $1.19 Million
Q2 2021 Aug 16, 2021	SELL	$23.7 - $39.27 $459,969 - $762,152	-19,408 Reduced 73.04%	7,162 $281,000
Q1 2021 May 17, 2021	SELL	$27.01 - $36.8 $158,467 - $215,905	-5,867 Reduced 18.09%	26,570 $751,000
Q4 2020 Feb 16, 2021	BUY	$27.51 - $34.36 $892,341 - $1.11 Million	32,437 New	32,437 $1.04 Million

Others Institutions Holding HCM

# of Institutions

Shares Held

14M

Call Options Held

2.7K

Put Options Held

3.7K

View Full List

About HUTCHMED (China) Ltd

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.96B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

More about HCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account